The addition of Rituximab (anti-CD20 monoclonal antibody) to chemotherapy has dramatically increased survival of non-Hodgkin’s lymphoma (NHL) patients. However, in view of the intrinsic immunosuppressive effect of this drug, new questions are emerging in clinical practice. Among these, the assessment and proper interpretation of HBV serological status in patients undergoing Rituximab-based chemotherapy are of special concern. This topic was the object of a recently interesting review published on your journa. However, in the last few months, two other studies were published, which investigated the incidence of HBV in NHL patients treated with Rituximab-based regimens.
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era
BEDOGNETTI D;ZOPPOLI, GABRIELE;SERTOLI, MARIO ROBERTO;ZANARDI E;BOCCARDO, FRANCESCO;GHIO, RICCARDO;FERRARINI, MANLIO;DE MARIA, ANDREA
2010-01-01
Abstract
The addition of Rituximab (anti-CD20 monoclonal antibody) to chemotherapy has dramatically increased survival of non-Hodgkin’s lymphoma (NHL) patients. However, in view of the intrinsic immunosuppressive effect of this drug, new questions are emerging in clinical practice. Among these, the assessment and proper interpretation of HBV serological status in patients undergoing Rituximab-based chemotherapy are of special concern. This topic was the object of a recently interesting review published on your journa. However, in the last few months, two other studies were published, which investigated the incidence of HBV in NHL patients treated with Rituximab-based regimens.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
